Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023 - Ascendis Pharma (NASDAQ:ASND)

— 52-week results from the Phase 3 PaTHway Trial showed that the skeletal dynamics of adult patients with chronic hypoparathyroidism treated with TransCon PTH trended toward a new steady state closer to age-appropriate

Related Keywords

Heidelberg ,Baden Wüberg ,Germany ,Denmark ,Canada ,Copenhagen ,Køavn ,Vancouver ,British Columbia ,Russia ,California ,United States ,Munich ,Bayern ,New Jersey ,Redwood City ,Japan ,Ukraine ,American ,Ascendis Pharma ,Taliya Khan ,American Association Of Bone Mineral Research ,European Union ,Company Phase ,Clinical Professor Of Medicine At Mcmaster University ,Exchange Commission ,Clinical Professor ,Mcmaster University ,Calcium Disorders Clinic ,Mcmaster University Medical Center ,American Association ,Mineral Research ,Palo Alto ,Ascendi Annual Report ,